We are live on ! Find out more
BCM

Bronte Capital Management Portfolio holdings

AUM $931M
1-Year Est. Return 47.97%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+47.97%
3 Year Est. Return
+122.73%
5 Year Est. Return
+132.88%
10 Year Est. Return
AUM
$1.12B
AUM Growth
+$127M
Cap. Flow
-$10M
Cap. Flow %
-0.9%
Top 10 Hldgs %
73.92%
Holding
31
New
3
Increased
10
Reduced
17
Closed
1

Sector Composition

Rank Sector Weight
1 Financials 22.71%
2 Communication Services 21.64%
3 Miscellaneous 18.92%
4 Healthcare 12.51%
5 Consumer Discretionary 10.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GOOGL icon
1
Alphabet (Google) Class A
GOOGL
$4.23T
$153M 13.63%
1,092,487
+56
+0% +$7.52K
BRK.B icon
2
Berkshire Hathaway Class B
BRK.B
$1.09T
$148M 13.21%
414,634
+5,023
+1% +$1.76M
REGN icon
3
Regeneron Pharmaceuticals
REGN
$80.8B
$128M 11.41%
145,421
+3,979
+3% +$3.28M
IBKR icon
4
Interactive Brokers
IBKR
$40.1B
$69.3M 6.19%
3,344,776
-20,136
-0.6% -$412K
AMZN icon
5
Amazon
AMZN
$2.71T
$61M 5.45%
401,476
+116,752
+41% +$16.4M
PINS icon
6
Pinterest
PINS
$10.3B
$52.4M 4.68%
1,414,696
+30,749
+2% +$966K
IWM icon
7
CALL
iShares Russell 2000 ETF
IWM
$77.1B
$50.4M 4.51%
+200,000
New +$35.8M
HLF icon
8
Herbalife
HLF
$1.25B
$47.3M 4.23%
3,102,717
-18,750
-0.6% -$259K
HIBB
9
DELISTED
Hibbett, Inc. Common Stock
HIBB
$43.5M 3.89%
604,211
-3,630
-0.6% -$203K
PM icon
10
Philip Morris
PM
$296B
$40M 3.58%
425,653
+21,633
+5% +$1.99M
IBB icon
11
iShares Biotechnology ETF
IBB
$10.5B
$38.2M 3.42%
281,528
-1,701
-0.6% -$208K
FCNCA icon
12
First Citizens BancShares
FCNCA
$23.9B
$37M 3.31%
26,090
-157
-0.6% -$220K
CTVA icon
13
Corteva
CTVA
$54.8B
$29.4M 2.62%
612,639
-3,688
-0.6% -$176K
MTCH icon
14
Match Group
MTCH
$10B
$27.4M 2.45%
751,733
+115,135
+18% +$3.89M
GHC icon
15
Graham Holdings Company
GHC
$4.78B
$15.6M 1.39%
22,408
-2,062
-8% -$1.28M
SQM icon
16
Sociedad Química y Minera de Chile
SQM
$20.6B
$10M 0.9%
166,619
+13,539
+9% +$716K
GOOG icon
17
Alphabet (Google) Class C
GOOG
$4.18T
$9.77M 0.87%
69,338
-422
-0.6% -$57.3K
VRTX icon
18
Vertex Pharmaceuticals
VRTX
$130B
$8.45M 0.75%
+20,760
New +$7.67M
BBWI icon
19
Bath & Body Works
BBWI
$3.44B
$8.18M 0.73%
189,515
-1,102
-0.6% -$37.2K
GIS icon
20
General Mills
GIS
$19.7B
$6.46M 0.58%
99,176
-39,630
-29% -$2.56M
MDLZ icon
21
Mondelez International
MDLZ
$79.3B
$4.85M 0.43%
66,929
+7,334
+12% +$503K
BNTX icon
22
BioNTech
BNTX
$24.9B
$2.47M 0.22%
23,364
-135
-0.6% -$13.6K
RSKD icon
23
Riskified
RSKD
$827M
$2.39M 0.21%
510,154
-2,951
-0.6% -$12.1K
RAMP icon
24
LiveRamp
RAMP
$2.31B
$2.31M 0.21%
+60,890
New +$1.96M
CTMX icon
25
CytomX Therapeutics
CTMX
$612M
$1.43M 0.13%
919,911
-5,334
-0.6% -$7.01K

Similar funds

Bronte Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Bronte Capital Management held 31 positions worth $1.12B, up 13% from $993M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Bronte Capital Management's Q4 2023 filing shows 3 new, 10 increased, 17 reduced and 1 closed positions. Its largest new stake was Vertex Pharmaceuticals: 20,760 shares worth $8.45M. The largest sale was Activision Blizzard, an estimated $6.53M.

By sector, the portfolio is most concentrated in Financials at 23% of assets, down from 25% a quarter earlier, followed by Communication Services and Miscellaneous.

  • Bronte Capital Management's largest Q4 2023 buy was Vertex Pharmaceuticals: 20,760 shares worth $8.45M.
  • Bronte Capital Management added most to Amazon in Q4 2023, an estimated $16.4M increase.
  • Bronte Capital Management's biggest Q4 2023 reduction was General Mills, cutting an estimated $2.56M.
  • Bronte Capital Management fully exited Activision Blizzard in Q4 2023, selling an estimated $6.53M.
  • Bronte Capital Management's ten largest holdings make up 74% of its $1.12B portfolio in Q4 2023.
  • Bronte Capital Management opened 3 new positions and closed 1 in Q4 2023.
  • Bronte Capital Management's portfolio value rose 13% quarter-over-quarter to $1.12B.

Based on Bronte Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.